Company / Return on Assets (ROA)
CRISPR Therapeutics AG Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-25.7%
FY2025
5-year range
-29.0% / 13.7%
FY2021-FY2025
Trend
-57.1%
vs FY2024
Sector context
#117 of 213
Health Care
What the data says
At -25.7%, CRISPR Therapeutics AG's return on assets (roa) ranks #117 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -33.7% in FY2018 to 13.7% in FY2021.
Based on SEC 10-K filings.
-25.7% in FY2025 with a 5-year CAGR of -6.6%.
Declined from -6.9% to -25.7% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +3.3pp
- 5-Year Change
- -6.6pp
- 10-Year Change
- -
Sector benchmark
#117 of 213 in Health CareTop 55% of 213This company -25.7% Sector average -24.1%
▼
-6.7% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 57.1% year-over-year.
- Currently 1.6pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
- Lowest return on assets (roa) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -25.7% | -57.1% |
| FY2024 | -16.3% | -137.2% |
| FY2023 | -6.9% | +76.2% |
| FY2022 | -29.0% | -311.3% |
| FY2021 | 13.7% | +171.9% |
| FY2020 | -19.1% | -404.3% |
| FY2019 | 6.3% | +118.6% |
| FY2018 | -33.7% | -33.9% |
| FY2017 | -25.2% | -274.9% |
| FY2016 | -6.7% | +58.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026